Alvotech SA, a leading global biotech company, has expanded its partnership with Advanz Pharma, a UK-based pharmaceutical company, to commercialize three additional biosimilars in Europe. The agreement grants Advanz Pharma exclusive rights to market biosimilar candidates for Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed biosimilar. This collaboration, which builds on previously partnered programs, underscores Advanz Pharma's commitment to enhancing access to rare disease and specialty medicines. The partnership involves development and commercial milestones worth up to US$180 million and includes a revenue-sharing model. Alvotech will handle development and supply, while Advanz Pharma will focus on registration and commercialization in Europe.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。